Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Proteomedix AG. (8/27/18). "Press Release: Proteomedix Raises CHF 5.2 Million in Financing Round".

Organisations Organisation Proteomedix AG
  Organisation 2 Altos Venture (CH)
Products Product Proclarix® blood-based prostate cancer test panel and risk score
  Product 2 venture capital
Index term Index term Proteomedix–SEVERAL: investment, 201808 financing round CHF5.2m from exising investors led by Altos Venture + incl ZKB
Persons Person Schiess, Ralph (Proteomedix 202001 CSO + Co-Founder before CEO)
  Person 2 Fischli, Walter (Altos Venture 201808 Chair + co-founder of Actelion)
     


ProteoMediX AG, a diagnostic company developing blood-based tests for the accurate diagnosis and prognosis of prostate cancer, has announced the successful closing of an equity financing round. The company raised CHF 5.2 million (€ 4.6 million) from existing investors.

Altos Venture (Allschwil, Switzerland), a Swiss venture capital firm chaired by Dr. Walter Fischli (co-founder of Actelion), led the financing round. All existing investors participated in this round, including Zürcher Kantonalbank and several private investors experienced in life science investments. Including the funds from this new round, ProteoMediX has raised a total of CHF 17 million (€ 15 million) in equity.

The new funds will enable ProteoMediX to continue the market preparations and start with the market development of its lead product for prostate cancer diagnosis. The blood-based test is intended as an aid in the diagnosis of prostate cancer, i.e. to inform men with elevated PSA (prostate specific antigen) about the likelihood of having prostate cancer. ProteoMediX’ test is based on a proprietary protein signature and addresses the problem of prostate cancer overdiagnosis resulting in numerous negative prostate biopsies and potential side effects such as infections or bleeding. The goal is to significantly reduce these negative biopsies (today, more than half of all prostate biopsies are negative). The promising results of several clinical studies showed that ProteoMediX’ test has the potential to significantly reduce overdiagnosis and identify high-grade cancer with high accuracy.

Dr. Ralph Schiess, CEO commented: "We are very pleased with the continuous financial support we receive. This reflects the continuous progress we made in the past and the potential of our approach for improving prostate cancer diagnosis". "We are delighted about the strong commitment from our existing investors. The additional funds allow us to advance our first product for the diagnosis of prostate cancer and start developing the market in Europe", said Christian Brühlmann, CFO of ProteoMediX.


Contact:

Ralph Schiess, CEO/ Christian Brühlmann, CFO/CBO
+41 44 733 40 90
info@proteomedix.com

   
Record changed: 2020-05-26

Advertisement

Picture [iito] No Tracking 650x80px

More documents for Proteomedix AG


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81




» top